Frequency Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 17.36 million compared to USD 21.5 million a year ago. Basic loss per share from continuing operations was USD 24.5 compared to USD 31 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.66 USD | +6.63% | +7.18% | +14.04% |
15/05 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
14/05 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.04% | 475M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- KRRO Stock
- News Korro Bio, Inc.
- Frequency Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022